Soleus Capital Management, L.P. Fate Therapeutics Inc Transaction History

Soleus Capital Management, L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$3.54 - $8.35 $3.08 Million - $7.26 Million	870,000 New	870,000 $6.39 Million
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $2.67 Million - $4.58 Million	-127,100 Reduced 65.38%	67,300 $1.51 Million
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $204,470 - $487,485	-11,500 Reduced 5.59%	194,400 $4.82 Million
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $5.88 Million - $11.9 Million	198,100 Added 2539.74%	205,900 $7.98 Million
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $373,152 - $501,852	7,800 New	7,800 $456,000
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $492,852 - $801,842	-6,830 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $109,775 - $290,937	-2,882 Reduced 29.67%	6,830 $621,000
Q3 2020 Nov 13, 2020	SELL	$30.41 - $40.5 $708,188 - $943,164	-23,288 Reduced 70.57%	9,712 $388,000
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $666,930 - $1.16 Million	33,000 New	33,000 $1.13 Million
Q1 2020 May 15, 2020	SELL	$17.28 - $31.88 $196,992 - $363,432	-11,400 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$13.39 - $20.73 $152,646 - $236,322	11,400 New	11,400 $223,000

177

113M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $126M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.